Cingulate (Cingulate) YoY EBITDA Growth : 91.51% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cingulate YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cingulate's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 91.51%.

Cingulate's EBITDA per Share for the three months ended in Mar. 2024 was $-0.56.

Cingulate YoY EBITDA Growth Historical Data

The historical data trend for Cingulate's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate YoY EBITDA Growth Chart

Cingulate Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

44.04

-373.90

47.21

13.78

Cingulate Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial												23.62	-51.88	17.26	7.79	91.51

Cingulate YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cingulate's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-24.504	-	-28.419)	/	\| -28.419 \|
=	13.78 %

Cingulate's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.563	-	-6.635)	/	\| -6.635 \|
=	91.51 %

Cingulate YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cingulate's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cingulate (Cingulate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 W. 47th Place, Kansas, KS, USA, 66205

Website

https://www.cingulate.com

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Executives

Jennifer L. Callahan	officer: Corporate Controller	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth	director, 10 percent owner	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer	director, 10 percent owner, officer: Chief Executive Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon	officer: EVP & General Counsel	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers	officer: EVP & Chief Operating Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum	director	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros	director	2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G	officer: EVP & Chief Financial Officer	C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher	director	275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy	director	2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva	officer: EVP & Chief Science Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams	officer: EVP & Chief Medical Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc	10 percent owner	1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205